%0 Journal Article
%T Assessment of the Diagnostic Value of Plasma Level of Von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction
%A Basant Magdy Abdulla
%A Aziza Abbas Ahmed
%A Dalia Mahmoud Eldawy
%A Lamiaa Ismail Ahmed
%J Open Journal of Blood Diseases
%P 110-123
%@ 2164-3199
%D 2022
%I Scientific Research Publishing
%R 10.4236/ojbd.2022.124012
%X <strong>Background:</strong><span style=\"font-family:;\" \"=\"\"> Von Willebrand Factor (VWF) is a large multimeric
plasma</span><span style=\"font-family:;\" \"=\"\"> </span><span style=\"font-family:;\" \"=\"\">gly</span><span style=\"font-family:;\" \"=\"\">-</span><span style=\"font-family:;\" \"=\"\">coprotein that plays an important role in primary haemostasis. VWF
together with ADAMTS13 plays a key role in arterial thrombosis. VWF is integral
for platelet adhesion to collagen fibres and atherosclerotic plaues and platelets
aggregation under high shear conditions. Upon vascular wall damage, plasma VWF
binds to collagen in the exposed endothelial matrix and platelet glycoprotein
triggers platelet aggregation and thrombous formation. In </span><span style=\"font-family:;\" \"=\"\">the </span><span style=\"font-family:;\" \"=\"\">early stages of acute
ischaemic stroke, VWF increased significantly and the ADAMTS13 level decreased.
The increase of plasma VWF and FVIII in </span><span style=\"font-family:;\" \"=\"\">a </span><span style=\"font-family:;\" \"=\"\">patient with ischaemic stroke indicated an increased
risk of complications and severe neurological deficit. <b>Objective</b></span><b><span style=\"font-family:;\" \"=\"\">:</span></b><span style=\"font-family:;\" \"=\"\"> to evaluate the validity of VWF and ADFAMTS13 as
diagnostic markers of cerebral infarction </span><span style=\"font-family:;\" \"=\"\">by</span><span style=\"font-family:;\" \"=\"\"> comparing the two markers</span><span style=\"font-family:;\" \"=\"\">¡¯</span><span style=\"font-family:;\" \"=\"\"> validity in diagnosis. <b>Methods:</b> this case
control study enrolled 38 cerebral </span><span style=\"font-family:;\" \"=\"\">infarction patients 20 acute infarction and 18
recurrent infarction. Patients were compared with 65 age and sex with control
patients. We performed </span><span style=\"font-family:;\" \"=\"\">the </span><span style=\"font-family:;\" \"=\"\">VWF assay using </span><span style=\"font-family:;\" \"=\"\">the </span><span style=\"font-family:;\" \"=\"\">minividas immunofluorescence technique and </span><span style=\"font-family:;\" \"=\"\">the </span><span style=\"font-family:;\" \"=\"\">ADAMTS13 assay using</span><span style=\"font-family:;\" \"=\"\"> the</span><span style=\"font-family:;\" \"=\"\"> ELISA technique.</span><span style=\"font-family:;\" \"=\"\"> </span><b><span style=\"font-family:;\" \"=\"\">Results:</span></b><span style=\"font-family:;\" \"=\"\"> VWF level of acute infarction patients (280.97 ¡À 109.83 IU/dl) while its
level in recurrent
%K VWF
%K ADAMTS13
%K Cerebral Infarction
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=121758